Search results
Results from the WOW.Com Content Network
Geographic atrophy (GA), also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, choriocapillaris) which can lead to a loss of central vision over time.
Drug Manufacturer Indication Avacincaptad pegol: To treat geographic atrophy secondary to age-related macular degeneration [4] Cipaglucosidase alfa: To treat late-onset Pompe disease with miglustat [4] Dabrafenib: Dostarlimab: Eflornithine: Elranatamab: To treat relapsed or refractory multiple myeloma after at least four lines of therapy [4 ...
Pegcetacoplan is indicated to treat adults with paroxysmal nocturnal hemoglobinuria. [8] [9] [11] In February 2023, the indication was updated to include the treatment of people with geographic atrophy secondary to age-related macular degeneration.
Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration. [1] Avacincaptad pegol is a complement inhibitor. [1] Avacincaptad pegol was approved for medical use in the United States in August 2023. [2] [3] [4]
Gildeuretinol is an investigational new drug being developed by Alkeus Pharmaceuticals for the treatment of retinal diseases, particularly Stargardt disease and geographic atrophy secondary to age-related macular degeneration (AMD).
In advanced stages of AMD, atrophy of the RPE (geographic atrophy) and/or development of new blood vessels (neovascularization) result in the death of photoreceptors and central vision loss. [citation needed] In the dry (nonexudative) form, drusen accumulates between the retina and the choroid, causing atrophy and scarring to the retina. In the ...
Lampalizumab is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.